KR20150018832A - 전신 마취약과 수소를 조합하여 이루어지는, 의약 - Google Patents
전신 마취약과 수소를 조합하여 이루어지는, 의약 Download PDFInfo
- Publication number
- KR20150018832A KR20150018832A KR20147035945A KR20147035945A KR20150018832A KR 20150018832 A KR20150018832 A KR 20150018832A KR 20147035945 A KR20147035945 A KR 20147035945A KR 20147035945 A KR20147035945 A KR 20147035945A KR 20150018832 A KR20150018832 A KR 20150018832A
- Authority
- KR
- South Korea
- Prior art keywords
- anesthetic
- hydrogen
- general
- medicament
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012125535 | 2012-05-31 | ||
| JPJP-P-2012-125535 | 2012-05-31 | ||
| PCT/JP2013/065094 WO2013180240A1 (ja) | 2012-05-31 | 2013-05-30 | 全身麻酔薬と、水素とを組み合わせてなる、医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150018832A true KR20150018832A (ko) | 2015-02-24 |
Family
ID=49673427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20147035945A Withdrawn KR20150018832A (ko) | 2012-05-31 | 2013-05-30 | 전신 마취약과 수소를 조합하여 이루어지는, 의약 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150079197A1 (enExample) |
| EP (1) | EP2857026A4 (enExample) |
| JP (1) | JP6168420B2 (enExample) |
| KR (1) | KR20150018832A (enExample) |
| CN (1) | CN104394873A (enExample) |
| AU (1) | AU2013268366A1 (enExample) |
| BR (1) | BR112014029260A2 (enExample) |
| CA (1) | CA2874579A1 (enExample) |
| HK (1) | HK1205450A1 (enExample) |
| IL (1) | IL235718A0 (enExample) |
| IN (1) | IN2014MN02090A (enExample) |
| MX (1) | MX2014014543A (enExample) |
| NZ (1) | NZ701553A (enExample) |
| RU (1) | RU2014152690A (enExample) |
| SG (1) | SG11201407489TA (enExample) |
| WO (1) | WO2013180240A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6253029B2 (ja) * | 2015-01-21 | 2017-12-27 | 大陽日酸株式会社 | 麻酔器用取付キット |
| US20180338995A1 (en) * | 2017-05-23 | 2018-11-29 | Perricone Hydrogen Water Company, Llc | Systems and methods for treatments using hydrogen and/or noble gases |
| US11129848B2 (en) * | 2017-08-08 | 2021-09-28 | Perricone Hydrogen Water Company, Llc | Medication enhancement using hydrogen |
| US20210222174A1 (en) * | 2018-06-29 | 2021-07-22 | John Mansell | Compositions and methods for the treatment of anesthesia-induced neurotoxicity |
| US11123365B2 (en) | 2019-11-18 | 2021-09-21 | Perricone Hydrogen Water Company, Llc | Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof |
| JP7019910B2 (ja) * | 2020-07-21 | 2022-02-16 | MiZ株式会社 | 薬の副作用、薬の副作用に関連する症状、および/または、治療に伴う副作用を予防および/または改善するための組成物 |
| CN117861037A (zh) * | 2022-10-11 | 2024-04-12 | 上海氢医医疗科技有限公司 | 氢气吸入治疗自闭症 |
| CN119303200A (zh) * | 2024-12-17 | 2025-01-14 | 山东百多安医疗器械股份有限公司 | 一种可以释放氢气减少神经损伤的麻醉机 |
-
2013
- 2013-05-30 MX MX2014014543A patent/MX2014014543A/es unknown
- 2013-05-30 WO PCT/JP2013/065094 patent/WO2013180240A1/ja not_active Ceased
- 2013-05-30 CN CN201380028933.5A patent/CN104394873A/zh active Pending
- 2013-05-30 AU AU2013268366A patent/AU2013268366A1/en not_active Abandoned
- 2013-05-30 NZ NZ701553A patent/NZ701553A/en not_active IP Right Cessation
- 2013-05-30 US US14/397,229 patent/US20150079197A1/en not_active Abandoned
- 2013-05-30 JP JP2014518736A patent/JP6168420B2/ja not_active Expired - Fee Related
- 2013-05-30 BR BR112014029260A patent/BR112014029260A2/pt not_active Application Discontinuation
- 2013-05-30 KR KR20147035945A patent/KR20150018832A/ko not_active Withdrawn
- 2013-05-30 CA CA2874579A patent/CA2874579A1/en not_active Abandoned
- 2013-05-30 RU RU2014152690A patent/RU2014152690A/ru unknown
- 2013-05-30 IN IN2090MUN2014 patent/IN2014MN02090A/en unknown
- 2013-05-30 HK HK15103729.5A patent/HK1205450A1/en unknown
- 2013-05-30 EP EP13796554.7A patent/EP2857026A4/en not_active Withdrawn
- 2013-05-30 SG SG11201407489TA patent/SG11201407489TA/en unknown
-
2014
- 2014-11-16 IL IL235718A patent/IL235718A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2874579A1 (en) | 2013-12-05 |
| WO2013180240A1 (ja) | 2013-12-05 |
| EP2857026A4 (en) | 2015-11-04 |
| US20150079197A1 (en) | 2015-03-19 |
| BR112014029260A2 (pt) | 2017-06-27 |
| JP6168420B2 (ja) | 2017-07-26 |
| SG11201407489TA (en) | 2014-12-30 |
| MX2014014543A (es) | 2015-06-05 |
| IN2014MN02090A (enExample) | 2015-09-04 |
| NZ701553A (en) | 2016-06-24 |
| RU2014152690A (ru) | 2016-07-20 |
| IL235718A0 (en) | 2015-01-29 |
| EP2857026A1 (en) | 2015-04-08 |
| AU2013268366A1 (en) | 2015-03-19 |
| JPWO2013180240A1 (ja) | 2016-01-21 |
| HK1205450A1 (en) | 2015-12-18 |
| CN104394873A (zh) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6168420B2 (ja) | 全身麻酔薬と、水素とを組み合わせてなる、医薬 | |
| Ait-Bali et al. | Pre-and postnatal exposure to glyphosate-based herbicide causes behavioral and cognitive impairments in adult mice: evidence of cortical ad hippocampal dysfunction | |
| Karen et al. | Effect of propofol in the immature rat brain on short-and long-term neurodevelopmental outcome | |
| Olivier et al. | Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring | |
| Ma et al. | Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain | |
| Parameshwaran et al. | Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus | |
| Fujimura et al. | Perinatal exposure to low-dose methylmercury induces dysfunction of motor coordination with decreases in synaptophysin expression in the cerebellar granule cells of rats | |
| Cui et al. | Reward ameliorates depressive-like behaviors via inhibition of the substantia innominata to the lateral habenula projection | |
| Nie et al. | Propofol attenuates isoflurane-induced neurotoxicity and cognitive impairment in fetal and offspring mice | |
| Kim et al. | P2X7 receptor differentially modulates astroglial apoptosis and clasmatodendrosis in the rat brain following status epilepticus | |
| Li et al. | Activation of glycine receptors in the lateral habenula rescues anxiety-and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats | |
| Chiang et al. | Beneficial effects of co-treatment with dextromethorphan on prenatally methadone-exposed offspring | |
| Luo et al. | Differential effects of general anesthetics on anxiety-like behavior in formalin-induced pain: involvement of ERK activation in the anterior cingulate cortex | |
| Jiang et al. | The GABAB receptor agonist STX209 reverses the autism-like behaviour in an animal model of autism induced by prenatal exposure to valproic acid | |
| Giri et al. | Pretreatment with minocycline improves neurogenesis and behavior performance after midazolam exposure in neonatal rats | |
| Barr et al. | Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience | |
| Ding et al. | CX3CR1 mediates nicotine withdrawal-induced hyperalgesia via microglial P38 MAPK signaling | |
| Flores et al. | Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats | |
| Harding et al. | Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats | |
| Ribeiro et al. | A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: an animal study | |
| Kurokawa et al. | Possible involvement of type 1 inositol 1, 4, 5-trisphosphate receptors up-regulated by dopamine D1 and D2 receptors in mouse nucleus accumbens neurons in the development of methamphetamine-induced place preference | |
| Iida et al. | Analgesic effect of linalool odor on oral ulcerative mucositis-induced pain in rats | |
| Wei et al. | Bumetanide attenuates sevoflurane‐induced neuroapoptosis in the developing dentate gyrus and impaired behavior in the contextual fear discrimination learning test | |
| Sun et al. | Interactions between astrocytes and neurons in the brainstem involved in restraint water immersion stress-induced gastric mucosal damage | |
| Mooney et al. | Prenatal exposure to ethanol affects postnatal neurogenesis in thalamus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20141222 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180525 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20180615 |